The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study

被引：0

作者：

Garcia, Jacqueline S. ^{[1
]}

Wei, Andrew H. ^{[2
,3
]}

Borate, Uma ^{[4
]}

Fong, Chun Yew ^{[5
]}

Baer, Maria R. ^{[6
]}

Nolte, Florian ^{[7
]}

Peterlin, Pierre ^{[8
]}

Jurcic, Joseph ^{[9
]}

Jacoby, Meagan ^{[10
,11
]}

Hong, Wen-Jen ^{[12
]}

Platzbecker, Uwe ^{[13
]}

Odenike, Olatoyosi ^{[14
,15
]}

Cunningham, Ilona ^{[16
]}

Zhou, Ying ^{[17
]}

Dunbar, Martin ^{[17
]}

Harb, Jason G. ^{[17
]}

Popovic, Relja ^{[17
]}

Tanwani, Poonam ^{[17
]}

Gopalakrishnan, Sathej ^{[18
]}

Wolff, Johannes ^{[17
]}

Garcia-Manero, Guillermo ^{[19
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Alfred Hosp, Dept Haematol, Melbourne, Vic, Australia

[3] Monash Univ, Melbourne, Vic, Australia

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA

[5] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia

[6] Univ Maryland, Sch Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[7] Charite, Dept Hematol & Oncol, Campus Benjamin Franklin, Berlin, Germany

[8] Nantes Univ Hosp, Hematol Dept, Nantes, France

[9] Columbia Univ, Med Ctr, Myelodysplast Syndromes Ctr, New York, NY USA

[10] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[14] Univ Chicago Med, Chicago, IL USA

[15] Comprehens Canc Ctr, Chicago, IL USA

[16] Univ Sydney, Concord Clin Sch, Sydney, NSW, Australia

[17] AbbVie Inc, N Chicago, IL USA

[18] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany

[19] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

BCL-2; inhibitor; combination therapy; higher-risk MDS; efficacy; MDS; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-141

引用

页码：S315 / S316

页数：2

共 50 条

[31] Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses
Finelli, Carlo
Parisi, Sarah
Follo, Matilde Y.
Clissa, Cristina
Fogli, Miriam
Mongiorgi, Sara
Bosi, Costanza
Capodanno, Isabella
Castagnari, Barbara
Candoni, Anna
Crugnola, Monica
Giannini, Maria Benedetta
Leonardi, Giovanna
Miglino, Maurizio
Rigolin, Gian Matteo
Russo, Domenico
Tosi, Patrizia
Pellagatti, Andrea
Boultwood, Jacqueline
Cocco, Lucio
Cavo, Michele
BLOOD, 2020, 136
[32] Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
Hwang, Kyung-Lim
Song, Moo-Kon
Shin, Jin
Na, Hae-Jung
Shin, Dong-Hun
Kim, Joong-Keun
Moon, Joon-Ho
Ahn, Jae-Sook
Song, Ik-Chan
Hong, Junshik
Lee, Gyeong-won
Chung, Joo-Seop
BLOOD RESEARCH, 2014, 49 (04) : 234 - 240
[33] The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group
Papageorgiou, Sotirios G.
Vasilatou, Diamantina
Kontos, Christos K.
Kotsianidis, Ioannis
Symeonidis, Argiris
Galanopoulos, Athanasios G.
Hatzimichael, Eleftheria
Megalakaki, Aekaterini
Poulakidas, Elias
Diamantopoulos, Panagiotis
Vassilakopoulos, Theodoros P.
Zikos, Panagiotis
Papadaki, Helen
Mparmparousi, Despoina
Bouronikou, Eleni
Panayiotidis, Panayiotis
Viniou, Nora-Athina
Pappa, Vassiliki
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 895 - 901
[34] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Sekeres, Mikkael A.
Schuster, Michael
Joris, Magalie
Krauter, Juergen
Maertens, Johan
Breems, Dimitri
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ching, Keith
O'Brien, Thomas
Stampino, Corrado Gallo
Ma, Weidong Wendy
Kudla, Arthur
Chan, Geoffrey
Zeidan, Amer M.
ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
[35] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Sekeres, Mikkael A.
List, Alan F.
Cuthbertson, David
Paquette, Ronald
Latham, Deborah
Afable, Manual
Paulic, Katarina
Loughran, Thomas P., Jr.
Maciejewski, Jaroslaw P.
BLOOD, 2008, 112 (11) : 88 - 89
[36] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Chen, James Yuhtyng
Johnson, Lisa
McKenna, Kelly Marie
Choi, Timothy S.
Duan, Jiaqi
Feng, Dongdong
Tsai, Jonathan M.
Garcia-Martin, Natalia
Sompalli, Kavitha
Maute, Roy
Vyas, Paresh
Majeti, Ravindra
Takimoto, Chris H. M.
Liu, Jie
Ramsingh, Giridharan
Chao, Mark
Volkmer, Jens-Peter
Weissman, Irving L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
DiNardo, Courtney D.
Daver, Naval
Jabbour, Elias
Kadia, Tapan
Borthakur, Gautam
Konopleva, Marina
Pemmaraju, Naveen
Yang, Hui
Wei, Yue
Wierda, William G.
Bueso-Ramos, Carlos E.
Patel, Keyur P.
Cortes, Jorge E.
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2014, 124 (21)
[38] Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
Chien, Kelly S.
Borthakur, Gautam
Naqvi, Kiran
Daver, Naval
Bravo, Guillermo Montalban
Cortes, Jorge E.
DiNardo, Courtney D.
Jabbour, Elias
Alvarado, Yesid
Andreeff, Michael
Bose, Prithviraj
Jain, Nitin
Sheppard, Kimberly
Klingner-Winton, Cheri
Pierce, Sherry A.
Dong, Xiao Qin
Soltysiak, Kelly A.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[39] ROLE OF ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA RECEIVING AZACITIDINE THERAPY
Avila, F.
Lorenzana, N.
Alonso, S.
Colado, E.
Bernal, T.
LEUKEMIA RESEARCH, 2017, 55 : S160 - S160
[40] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Berdeja, Jesus G.
Abaza, Yasmin
Jabbour, Elias
Essell, James
Lyons, Roger M.
Ravandi, Farhad
Maris, Michael
Heller, Brian
DeZern, Amy E.
Babu, Sunil
Wright, David
Anz, Bertrand
Boccia, Ralph
Komrokji, Rami S.
Kuriakose, Philip
Reeves, James
Sekeres, Mikkael A.
Kantarjian, Hagop M.
Ghalie, Richard
Roboz, Gail J.
CANCER, 2017, 123 (06) : 994 - 1002

← 1 2 3 4 5 →